WO2005030224A1 - Analgesiques et/ou anti-inflammatoires nitrosyles a activite antivirale - Google Patents
Analgesiques et/ou anti-inflammatoires nitrosyles a activite antivirale Download PDFInfo
- Publication number
- WO2005030224A1 WO2005030224A1 PCT/EP2004/051551 EP2004051551W WO2005030224A1 WO 2005030224 A1 WO2005030224 A1 WO 2005030224A1 EP 2004051551 W EP2004051551 W EP 2004051551W WO 2005030224 A1 WO2005030224 A1 WO 2005030224A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- group
- integer
- equal
- acid
- branched
- Prior art date
Links
- 0 *CC1CCCC1 Chemical compound *CC1CCCC1 0.000 description 5
- JQBKLIMXWCGANW-UHFFFAOYSA-O CC(C(C(C=C)N1C)OC)=C(C)[SH+]1=O Chemical compound CC(C(C(C=C)N1C)OC)=C(C)[SH+]1=O JQBKLIMXWCGANW-UHFFFAOYSA-O 0.000 description 1
- BGWARITZNFBKAZ-UHFFFAOYSA-N CC(C=CC1C2)=CC1=CC=C2OC Chemical compound CC(C=CC1C2)=CC1=CC=C2OC BGWARITZNFBKAZ-UHFFFAOYSA-N 0.000 description 1
- HNDPOFALDRYJBZ-UHFFFAOYSA-N CN(c(cc(CCC1=O)c1c1)c1Sc(ccc(F)c1)c1F)S(C)(=O)=O Chemical compound CN(c(cc(CCC1=O)c1c1)c1Sc(ccc(F)c1)c1F)S(C)(=O)=O HNDPOFALDRYJBZ-UHFFFAOYSA-N 0.000 description 1
- CHIDZKYQYRPKNP-UHFFFAOYSA-N Cc(cc1)ccc1-c1cc(C(F)(F)F)n[n]1C Chemical compound Cc(cc1)ccc1-c1cc(C(F)(F)F)n[n]1C CHIDZKYQYRPKNP-UHFFFAOYSA-N 0.000 description 1
- KHSDNLGBBHFIAF-UHFFFAOYSA-N Cc1c(C)[o]nc1-c1ccccc1 Chemical compound Cc1c(C)[o]nc1-c1ccccc1 KHSDNLGBBHFIAF-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
- A61K31/24—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group having an amino or nitro group
- A61K31/245—Amino benzoic acid types, e.g. procaine, novocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/60—Salicylic acid; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
Definitions
- the present invention relates to the use of drugs for treating viral diseases and/or their complications. More specifically, the present invention relates to the use of nitroderivatives for treatment of influenza, cold and viral 10 infections affecting the cardiovascular system, in particular the heart muscle.
- the viral infections are very diffused.
- the cold and influenza are the common infectious diseases of the respiratory tract caused by different viruses (rhinovirus, 15 influenza viruses) .
- the influenza produces symptoms that are more severe, such as a fever, runny nose, sore throat, cough, headache and muscle aches. Complications may prolong the illness, some people develop secondary bacterial infections such as otitis 20 media, sinuses, bronchitis and pneumonia.
- Vaccination is the best way to avoid contracting influenza and several antiviral drugs can be used to prevent infection and are also helpful in treating people who have influenza. 25
- the drawback of vaccines is that the virus can change each year.
- Amantadine and rimantadine are older antiviral drugs that offer protection against influenza type A but not influenza type B. These drugs can cause side effects such 30 as stomach upset, nervousness and sleeplessness.
- New analogs, oseltamivir and zanamivirm can prevent infection with either influenza virus types.
- the use of antiviral drugs does not eliminate the risk of complications and these drugs work only if taken in the first day or two of illness.
- the viral infections affecting the heart muscle are caused by different viruses such as coxsackie, adenovirus, and echovirus.
- the therapeutic treatment is generally unsatisfactory for the viral myocarditis .
- the need was felt to have available compounds active in viral infections, specifically those affecting the cardiovascular system, in particular the heart muscle, and for the prevention and/or treatment of influenza and cold. It has been surprisingly and unexpectedly found by the Applicant that it is possible to solve the above technical problem with specific nitroderivatives as described hereunder .
- c and d are independently 0 or 1;
- R D is selected from the group consisting of H, a linear or branched C1-C12 alkyl, C-C ⁇ 2 alkenyl; when c is equal to 0 , d is 1, R A is selected from the group consisting of:
- R c is selected from the group consisting of H, halogen, amino, R E CONH- and -OCOR;
- R D is H, OH, halogen, a linear or branched C1-C4 alkyl, a linear or branched C1-C4 alkoxyl, trifluoromethyl, amino, mono- or di-(C ⁇ C 4 ) alkylamino;
- R F ' is H and a linear or branched C1-C 5 alkyl; e is 0 or 1; M is carbon or nitrogen atom; when c is equal to 1, d is equal to 1, R B is hydrogen, R A is selected from the group consisting of:
- R is H or CH 3 and ⁇ r is Cl or F; when c is equal to 1, d is equal to 1 and R B is CH 3 , R A is selected from the group consisting of:
- R A is selected from the group consisting of:
- R D is as above defined
- R G is selected from the group consisting of:
- R H is phenyl or cyclohexyl
- Y is a bivalent radical having the following meaning: a) - linear or branched C1-C20 alkylene, preferably having from 2 to 5 carbon atoms; cycloalkylene with 5 to 7 carbon atoms into cycloalkylene ring, the ring being optionally substituted with side chains R 1 , wherein R 1 is linear or branched alkyl with from 1 to 10 carbon atoms, preferably CH 3 ; b)
- n is an integer from 0 to 20, and nl is an integer from 1 to 20 as above defined;
- nl is as defined above and n2 is an integer from 0 to 2;
- nl and R ? are as above defined, R 3 is H or COCH 3 ; with the proviso that when Y is selected from bivalent radicals mentioned under b) -f) , the -ONO2 group is linked to a -CH 2 group; g) R 2 R 2 —(CH-CH ⁇ X ⁇ CH-CHj- —(CH 2 -CH-X 2 ) n —CH 2 -CH- R 2 R 2 wherein X 2 is -0- or -S-, n3 is an integer from 1 to preferably from 1 to 4, R ? is as above defined; h)
- n4 is an integer from 0 to 10
- n5 is an integer from 1 to 10
- R 4 , R 5 , R 6 , R 7 are the same or different, and are H or straight or branched C1-C4 alkyl, preferably R 4 , R 5 , R 6 , R 7 are H; and wherein the -ON0 2 group is bound to
- n5 being as defined above;
- Y 2 is a 5 or 6 member saturated, unsaturated or aromatic heterocyclic ring, containing one or more heteroatoms selected from nitrogen, oxygen, sulfur, and selected for example from
- Non limiting examples of non-steroidal anti- inflammatory, analgesic and antipyretic drugs (A-OH or A-H) used in the present invention are:
- the COX-2 inhibitors used in the present invention are selected from the group consisting of: Celecoxib, Valdecoxib, JTE-522 (Tilmacoxib) , COX-189 (Lumiracoxib) , Nimesulide, N- (4-nitro-2-cycloexyloxy- phenyl)methanesulfonanilide (NS-398) and N-[6-[(2,4- difluorophenyl) thio] -2, 3-dihydro-l-oxo-lH-inden-5-yl] - methanesulfonamide (L-745337) .
- the compounds of formula (I), according to the present invention when they contain in the molecule one salifiable nitrogen atom, can be transformed into the corresponding salts by reaction in organic solvent such as acetonitrile, tetrahydrofuran with the corresponding organic or inorganic acid.
- organic acids are: oxalic, tartaric, maleic, succinic, citric acid.
- inorganic acids are: nitric, hydrochloric, sulphuric, phosphoric acid. Salts with nitric or hydrochloric acid are preferred.
- the compounds of the invention which have one or more asymmetric carbon atoms can exist as the optically pure enantiomers, pure diastereomers, enantiomers mixtures, diastereomers mixtures, enantiomer racemic mixtures, racemates or racemate mixtures.
- A is selected from the group consisting of: Ha
- c and d are independently 0 or 1;
- R B is selected from the group consisting of H, a linear or branched C1-C12 alkyl; when c is equal to 0 , d is 1, R A is selected from the group consisting of:
- R c is -OCOCH 3 in ortho-position with respect to -CO- and R D is H; when c is equal to 1, d is equal to 1 and R B is CH 3 , R A is selected from the group consisting of:
- R A is:
- Y is a bivalent radical having the following meaning: a) linear Ci-C ⁇ alkylene, preferably having from 3 to 5 carbon atoms; b)
- n is an integer from 0 to 5
- nl is an integer from 1 to 5
- nl is as defined above and n2 is an integer from 0 to 2;
- Xi -OCO- or -COO- and R 2 is H or CH 3 ;
- nl and R 2 are as above defined, R 3 is H or COCH 3 ; with the proviso that when Y is selected from bivalent radicals mentioned under b) -f) , the -ON0 2 group is linked to a -CH2 group; g )
- X 2 is -0- or -S-, n3 is an integer from 1 to 4 , preferably 1 , R 7 is as above defined; h)
- n4 is an integer from 0 to 3
- n5 is an integer from 1 to 3
- R 4 , R 5 , R 6 , R 7 are the same and are H; and wherein the -ONO2 group is bound to ⁇ [C] ⁇ 3
- Y is a 6 member saturated, unsaturated or aromatic heterocyclic ring, containing one or more atoms of nitrogen and selected for example from
- the amount on a molar basis of the active principle in said formulations is the same, or lower, with respect to that used as anti-inflammatory, analgesic and antipyretic drug of the corresponding precursor drug.
- the daily administrable doses are those of the precursor drugs, or optionally lower.
- the daily doses can be found in the publications of the field, such as for example in "Physician's Desk reference". The following examples are to further illustrate the invention without limiting it.
- ECP- no cytopathic effect induced by the virus
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Emergency Medicine (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP03292378.1 | 2003-09-26 | ||
EP03292378 | 2003-09-26 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2005030224A1 true WO2005030224A1 (fr) | 2005-04-07 |
Family
ID=34384697
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2004/051551 WO2005030224A1 (fr) | 2003-09-26 | 2004-07-20 | Analgesiques et/ou anti-inflammatoires nitrosyles a activite antivirale |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2005030224A1 (fr) |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005070006A3 (fr) * | 2004-01-22 | 2005-11-03 | Nitromed Inc | Composes nitroses et/ou nitrosyles, compositions et procede pour les utiliser |
US7087630B2 (en) | 2002-06-27 | 2006-08-08 | Nitromed, Inc. | Cyclooxygenase 2 selective inhibitors, compositions and methods of use |
WO2007060112A1 (fr) | 2005-11-23 | 2007-05-31 | Nicox S.A. | Derives d’acide salicylique |
US7521435B2 (en) | 2005-02-18 | 2009-04-21 | Pharma Diagnostics, N.V. | Silicon containing compounds having selective COX-2 inhibitory activity and methods of making and using the same |
WO2012143141A2 (fr) | 2011-04-21 | 2012-10-26 | Institut National De La Recherche Agronomique | Compositions antivirales dirigees contre la nucleoproteine des virus influenza |
WO2014111957A1 (fr) | 2013-01-21 | 2014-07-24 | Apparao Satyam | Promédicaments d'agents thérapeutiques libérant de l'oxyde nitrique |
WO2017153950A1 (fr) * | 2016-03-10 | 2017-09-14 | Biotech Innovations Spółka Z Ograniczoną Odpowiedzialnością | Inhibiteurs de nucléase du virus de la grippe (complexe de polymérases) |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5861426A (en) * | 1994-05-10 | 1999-01-19 | Nicox S.A. | Nitro compounds of the formula A-Xi -NO2 and their compositions having anti-inflammatory, analgesic and anti-thrombotic activities |
WO2001045703A1 (fr) * | 1999-12-23 | 2001-06-28 | Nitromed, Inc. | Inhibiteurs de cyclooxygenase-2 nitroses et nitrosyles, compositions et procedes d'utilisation |
EP1219306A1 (fr) * | 2000-12-29 | 2002-07-03 | Nicox S.A. | Compositions contenant des cyclodextrines et des médicaments libérant le NO |
WO2003013432A2 (fr) * | 2001-08-10 | 2003-02-20 | Nitromed, Inc. | Procedes d'utilisation de nouveaux composes de nitrate organique contenant du soufre |
-
2004
- 2004-07-20 WO PCT/EP2004/051551 patent/WO2005030224A1/fr unknown
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5861426A (en) * | 1994-05-10 | 1999-01-19 | Nicox S.A. | Nitro compounds of the formula A-Xi -NO2 and their compositions having anti-inflammatory, analgesic and anti-thrombotic activities |
WO2001045703A1 (fr) * | 1999-12-23 | 2001-06-28 | Nitromed, Inc. | Inhibiteurs de cyclooxygenase-2 nitroses et nitrosyles, compositions et procedes d'utilisation |
EP1219306A1 (fr) * | 2000-12-29 | 2002-07-03 | Nicox S.A. | Compositions contenant des cyclodextrines et des médicaments libérant le NO |
WO2003013432A2 (fr) * | 2001-08-10 | 2003-02-20 | Nitromed, Inc. | Procedes d'utilisation de nouveaux composes de nitrate organique contenant du soufre |
Non-Patent Citations (3)
Title |
---|
DE CLERCQ E ET AL: "5-Nitro-2'-deoxyuridine and 5-nitro-2'-deoxyuridine 5'-monophosphate: Antiviral activity and inhibition of thymidylate synthetase in vivo", MOLECULAR PHARMACOLOGY 1978 UNITED STATES, vol. 14, no. 3, 1978, pages 422 - 430, XP008036061 * |
FIORUCCI S ET AL: "A NO-releasing derivative of acetaminophen spares the liver by acting at several checkpoints in the Fas pathway", BRITISH JOURNAL OF PHARMACOLOGY 2002 UNITED KINGDOM, vol. 135, no. 3, 2002, pages 589 - 599, XP008036060, ISSN: 0007-1188 * |
KHALILI P ET AL: "Biochemical and pharmacokinetic evaluation of a novel pyrimidine nucleoside nitric oxide donor as a potential anticancer/antiviral agent", EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES 2003 NETHERLANDS, vol. 19, no. 4, 2003, pages 305 - 313, XP008036045, ISSN: 0928-0987 * |
Cited By (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7087630B2 (en) | 2002-06-27 | 2006-08-08 | Nitromed, Inc. | Cyclooxygenase 2 selective inhibitors, compositions and methods of use |
US7442802B2 (en) | 2002-06-27 | 2008-10-28 | Nitromed, Inc. | Cyclooxygenase-2 selective inhibitors, compositions and methods of use |
WO2005070006A3 (fr) * | 2004-01-22 | 2005-11-03 | Nitromed Inc | Composes nitroses et/ou nitrosyles, compositions et procede pour les utiliser |
US7521435B2 (en) | 2005-02-18 | 2009-04-21 | Pharma Diagnostics, N.V. | Silicon containing compounds having selective COX-2 inhibitory activity and methods of making and using the same |
WO2007060112A1 (fr) | 2005-11-23 | 2007-05-31 | Nicox S.A. | Derives d’acide salicylique |
WO2012143141A2 (fr) | 2011-04-21 | 2012-10-26 | Institut National De La Recherche Agronomique | Compositions antivirales dirigees contre la nucleoproteine des virus influenza |
FR2974299A1 (fr) * | 2011-04-21 | 2012-10-26 | Agronomique Inst Nat Rech | Compositions antivirales dirigees contre la nucleoproteine des virus influenza |
WO2012143141A3 (fr) * | 2011-04-21 | 2012-12-13 | Institut National De La Recherche Agronomique | Compositions antivirales dirigees contre la nucleoproteine des virus influenza |
US9783482B2 (en) | 2011-04-21 | 2017-10-10 | Institut National De La Recherche Agronomique | Antiviral compositions directed against the influenza virus nucleoprotein |
WO2014111957A1 (fr) | 2013-01-21 | 2014-07-24 | Apparao Satyam | Promédicaments d'agents thérapeutiques libérant de l'oxyde nitrique |
US9844599B2 (en) | 2013-01-21 | 2017-12-19 | Apparao Satyam | Nitric oxide releasing produgs of therapeutic agents |
WO2017153950A1 (fr) * | 2016-03-10 | 2017-09-14 | Biotech Innovations Spółka Z Ograniczoną Odpowiedzialnością | Inhibiteurs de nucléase du virus de la grippe (complexe de polymérases) |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP7366385B2 (ja) | ヘルペスウイルス誘発疾患の処置のための方法および組成物 | |
ES2304798T3 (es) | Sales de acido (r)-2-(3-benzoilfenil)propionico y preparaciones farmaceuticas que las contienen. | |
EA201500266A1 (ru) | Ингибиторы репликации вирусов гриппа | |
KR102537043B1 (ko) | 조합 치료요법용 약학 조성물 | |
RU2010141823A (ru) | Соединения и способ снижения мочевой кислоты | |
JP2011051993A5 (fr) | ||
JP2006104186A (ja) | 感冒用医薬組成物 | |
RU2342398C2 (ru) | Новые нестероидные противовоспалительные вещества, составы и способы их применения | |
CA2415577A1 (fr) | Utilisation d'inhibiteurs cox-2 pour la prevention de l'immunodeficience | |
WO2005030224A1 (fr) | Analgesiques et/ou anti-inflammatoires nitrosyles a activite antivirale | |
EA015132B1 (ru) | Лекарственное средство для лечения вирусных инфекций | |
EA018079B1 (ru) | Применение производных индола в качестве активаторов nurr-1 при лечении болезни паркинсона | |
EA200900868A1 (ru) | КОМБИНИРОВАННАЯ ТЕРАПИЯ ЗАБОЛЕВАНИЙ НИЖНИХ МОЧЕВЫВОДЯЩИХ ПУТЕЙ С ИСПОЛЬЗОВАНИЕМ ЛИГАНДОВ α2δ И НЕСТЕРОИДНЫХ ПРОТИВОВОСПАЛИТЕЛЬНЫХ ПРЕПАРАТОВ (НПВП) | |
EA200800071A1 (ru) | Производные бензофуранила как ингибиторы 5-нт6-рецептора | |
JP5053665B2 (ja) | 催眠用医薬組成物 | |
Botting | Antipyretic therapy | |
TW200301100A (en) | Treatment of neurodegenerative and cardiovascular disorders | |
JPH09511755A (ja) | 新規な治療方法 | |
ES2270634T3 (es) | Conversion de compuestos de inhibicion de cox que no son inhibidores selectivos de cox-2 en derivados que son inhibidores selectivos de cox-2. | |
US20020147206A1 (en) | Combination treatment of multiple sclerosis (MS), other demyelinating conditions and peripheral neuropathy, especially painful neuropathies and diabetic neuropathy | |
JP2008115168A (ja) | 抗アデノウイルス剤 | |
EA200500942A1 (ru) | Средство для лечения болезней суставов | |
AU2013250891B2 (en) | Materials and methods for prevention and treatment of viral infections | |
JP6100510B2 (ja) | 抗感冒剤 | |
JP6926192B2 (ja) | N,n−ビス−2−メルカプトエチルイソフタルアミドの新規用途 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |